Creative Medical Technology Holdings (CELZ) Other Non-Current Assets (2021 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Other Non-Current Assets of $3281.0 for Q1 2026, little changed year-over-year from $3281.0 in Q1 2025, and little changed quarter-over-quarter from $3281.0 in Q4 2025.
Creative Medical Technology Holdings (CELZ) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Other Non-Current Assets for 6 consecutive years, with $3281.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets changed 0.0% year-over-year to $3281.0; the TTM figure through Mar 2026 stood at $3281.0 (changed 0.0% YoY), while the FY2025 annual figure was $3281.0, changed 0.0% from the prior year.
- Other Non-Current Assets held at $3281.0 in Q1 2026 per CELZ's latest filing, from $3281.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $3281.0 in Q1 2022 and bottomed at $3281.0 in Q1 2022.
- Historically, Other Non-Current Assets has averaged $3281.0 across 5 years, with a median of $3281.0 in 2022.
- On a YoY basis, Other Non-Current Assets climbed as much as 0.0% in 2022 and fell as far as 0.03% in 2022.
- Creative Medical Technology Holdings' Other Non-Current Assets stood at $3281.0 in 2022, then changed by 0.0% to $3281.0 in 2023, then changed by 0.0% to $3281.0 in 2024, then changed by 0.0% to $3281.0 in 2025, then changed by 0.0% to $3281.0 in 2026.
- Business Quant data shows CELZ's Other Non-Current Assets at $3281.0 in Q1 2026, $3281.0 in Q4 2025, and $3281.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 62.96 Mn |
| 10 | Creative Medical Technology Holdings | 1.83 Mn | 1.83 Mn | - | 3,281.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3,281.00 |
| Mar 31, 2026 | 3,281.00 |
| Dec 31, 2025 | 3,281.00 |
| Sep 30, 2025 | 3,281.00 |
| Jun 30, 2025 | 3,281.00 |
| Mar 31, 2025 | 3,281.00 |
| Dec 31, 2024 | 3,281.00 |
| Sep 30, 2024 | 3,281.00 |
| Jun 30, 2024 | 3,281.00 |
| Mar 31, 2024 | 3,281.00 |
| Dec 31, 2023 | 3,281.00 |
| Sep 30, 2023 | 3,281.00 |
| Jun 30, 2023 | 3,281.00 |
| Mar 31, 2023 | 3,281.00 |
| Dec 31, 2022 | 3,281.00 |
| Sep 30, 2022 | 3,281.00 |
| Jun 30, 2022 | 3,281.00 |
| Mar 31, 2022 | 3,281.00 |
| Dec 31, 2021 | 3,281.00 |
| Sep 30, 2021 | 3,282.00 |